NCT02781727 - A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

January 17, 2019

Study Completion Date

January 17, 2019

Conditions

Growth Hormone Deficiency, PediatrichGH (Human Growth Hormone)Endocrine System DiseasesHormonesPituitary Diseases

Interventions

DRUG

Once weekly subcutaneous injection of TransCon hGH

Once weekly subcutaneous injection

DRUG

Once daily subcutaneous injection of Genotropin

Once daily subcutaneous injection

Trial Locations (53)

1023

Ascendis Pharma Investigational Site, Grafton

3168

Ascendis Pharma Investigational Site, Clayton

9010

Ascendis Pharma Investigational Site, Varna

11501

Ascendis Pharma Investigational Site, Mineola

11527

Ascendis Pharma Investigational Site, Athens

20157

Ascendis Pharma Investigational Site, Milan

32207

Ascendis Pharma Investigational Site, Jacksonville

32806

Ascendis Pharma Investigational Site, Orlando

35100

Ascendis Pharma Investigational Site, Izmir

35233

Ascendis Pharma Investigational Site, Birmingham

38039

Ascendis Pharma Investigational Site, Melikgazi

39216

Ascendis Pharma Investigational Site, Jackson

55102

Ascendis Pharma Investigational Site, Saint Paul

61080

Ascendis Pharma Investigational Site, Trabzon

61093

Ascendis Pharma Investigational Site, Kharkiv

65031

Ascendis Pharma Investigational Site, Odesa

72202

Ascendis Pharma Investigational Site, Little Rock

73104

Ascendis Pharma Investigational Site, Oklahoma City

75235

Ascendis Pharma Investigational Site, Dallas

76104

Ascendis Pharma Investigational Site, Fort Worth

80112

Ascendis Pharma Investigational Site, Centennial

90048

Ascendis Pharma Investigational Site, Los Angeles

92868

Ascendis Pharma Investigational Site, Orange

97239

Ascendis Pharma Investigational Site, Portland

98405

Ascendis Pharma Investigational Site, Tacoma

125373

Ascendis Pharma Investigational Site, Moscow

127994

Ascendis Pharma Investigational Site, Moscow

160022

Ascendis Pharma Investigational Site, Vologda

191144

Ascendis Pharma Investigational Site, Saint Petersburg

194100

Ascendis Pharma Investigational Site, Saint Petersburg

220020

Ascendis Pharma Investigational Site, Minsk

394024

Ascendis Pharma Investigational Site, Voronezh

410054

Ascendis Pharma Investigational Site, Saratov

420138

Ascendis Pharma Investigational Site, Kazan'

426009

Ascendis Pharma Investigational Site, Izhevsk

443079

Ascendis Pharma Investigational Site, Samara

450008

Ascendis Pharma Investigational Site, Ufa

603136

Ascendis Pharma Investigational Site, Nizhny Novgorod

620022

Ascendis Pharma Investigational Site, Krasnoyarsk

630048

Ascendis Pharma Investigational Site, Novosibirsk

634050

Ascendis Pharma Investigational Site, Tomsk

644001

Ascendis Pharma Investigational Site, Omsk

700111

Ascendis Pharma Investigational Site, Iași

03756

Ascendis Pharma Investigational Site, Lebanon

0075

Ascendis Pharma Investigational Site, Yerevan

0144

Ascendis Pharma Investigational Site, Tbilisi

0159

Ascendis Pharma Investigational Site, Tbilisi

0162

Ascendis Pharma Investigational Site, Tbilisi

00165

Ascendis Pharma Investigational Site, Roma

80-952

Ascendis Pharma Investigatonal Site, Gdansk

02-691

Ascendis Pharma Investigational Site, Warsaw

01021

Ascendis Pharma Investigational Site, Kyiv

04114

Ascendis Pharma Investigational Site, Kyiv

All Listed Sponsors

lead

Ascendis Pharma Endocrinology Division A/S

INDUSTRY